Compare PLYX & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLYX | NRC |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.8M | 428.2M |
| IPO Year | N/A | N/A |
| Metric | PLYX | NRC |
|---|---|---|
| Price | $6.15 | $15.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.2K | ★ 98.6K |
| Earning Date | 01-01-0001 | 02-03-2026 |
| Dividend Yield | N/A | ★ 4.01% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $137,390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $31.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.35 | $9.76 |
| 52 Week High | $48.91 | $22.79 |
| Indicator | PLYX | NRC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.73 |
| Support Level | N/A | $14.93 |
| Resistance Level | N/A | $16.45 |
| Average True Range (ATR) | 0.00 | 1.46 |
| MACD | 0.00 | -0.77 |
| Stochastic Oscillator | 0.00 | 6.07 |
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.